AI assistant
Sending…
Bio Green Med Solution, Inc. — Director's Dealing 2025
Feb 28, 2025
35092_dirs_2025-02-28_c86d4831-fa5c-4de4-b8d4-4e0bfa8f7c0f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Cyclacel Pharmaceuticals, Inc. (CYCC)
CIK: 0001130166
Period of Report: 2025-02-26
Reporting Person: Ben-Tzvi Avraham (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-02-26 | Non-Qualified Stock Option (Right to Buy) | $0.33 | A | 700000 | Acquired | 2035-02-26 | Common Stock (700000) | Direct |
Footnotes
F1: On February 26, 2025 (the "Grant Date"), the Reporting Person was granted 700,000 Non-Qualified Stock Options to purchased shares of common stock (the "Common Stock") of Cyclacel Pharmaceuticals, Inc. (the "Company") in consideration of his services as a director of the Company. The option grant became exercisable on the Grant Date.
More from Bio Green Med Solution, Inc.
Interim / Quarterly Report
2026
May 15
Regulatory Filings
2026
Apr 13
Annual Report
2026
Mar 30
Regulatory Filings
2026
Jan 12
Regulatory Filings
2025
Nov 28
Annual Report
2025
Nov 26
Director's Dealing
2025
Nov 14
Director's Dealing
2025
Nov 14
Major Shareholding Notification
2025
Nov 14
Interim / Quarterly Report
2025
Nov 13